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Voiding Dysfunction
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Intravesical Prostatic Protrusion Detected by Transrectal 
Ultrasonography in Patients with Benign Prostatic Hyperplasia
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Hong Sang Moon 
Department of Urology, Hanyang University College of Medicine, Seoul, Korea
Purpose: To analyze the effectiveness of tamsulosin 0.2 mg once daily for 3 months ac-
cording to the degree of intravesical prostatic protrusion (IPP) in patients with benign 
prostatic hyperplasia (BPH). 
Materials and Methods: A total of 134 BPH patients over 40 years of age treated with 
tamsulosin 0.2 mg between January 2007 and January 2009 were enrolled 
retrospectively. The patients were classified into three groups according to the degree 
of IPP: below 5 mm (group A), between 5 and 10 mm (group B), and over 10 mm (group 
C). Prostate volume, prostate-specific antigen (PSA), prostatic urethral length (PUL), 
and prostatic adenoma urethral length (PAUL) were evaluated before treatment. 
International Prostate Symptom Score and Quality of Life (IPSS/QoL), maximal urine 
flow rate (Qmax), and postvoid residual (PVR) volume were measured before treatment, 
and improvement in the three groups was compared after 3 months.
Results: The mean age of the patients was 65.01±7.38 years. Mean IPPs were 0.90±1.39
mm (group A, n=90), 6.92±1.10 mm (group B, n=24), and 16.60±4.06 mm (group C, 
n=20). Prostate volume, PUL, PAUL, PSA, Qmax, and PVR showed significant correla-
tions with IPP (p＜0.05), but not with IPSS/QoL score (p＞0.05). Comparison of parame-
ters before and after 3 months showed that medication improved total IPSS and sub-
scores (p＜0.001), QoL (p＜0.001), Qmax (p＜0.001), and PVR (p=0.030) in group A. In 
group B, it improved total IPSS (p=0.01), irritative subscore (p＜0.001), and obstructive 
subscore (p=0.03). In group C, only total IPSS (p=0.01) and irritative score (p＜0.001) 
were significantly improved.
Conclusions: Tamsulosin may be more effective in improving symptom scores and 
Qmax in patients with mild IPP than in those with moderate or severe IPP.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a progressive dis-
ease that has been on the rise in men over 50 [1]. The in-
cidence of BPH is thought to rapidly increase in an aging 
society. 
Transrectal ultrasonography (TRUS) is widely used be-
cause it can estimate prostate volume, shape, and the pres-
ence of adenoma and can evaluate anatomical structure 
through the application of noninvasive methods. Further-
more, TRUS permits a more accurate evaluation of the 
prostate than does computed tomography or magnetic res-
onance imaging. Intravesical prostatic protrusion (IPP) is 
the result of morphological changes leading to protrusion 
of hypertrophied prostate tissue into the bladder. It is 
known that more extensive IPP can lead to increased void-Korean J Urol 2012;53:92-97
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FIG. 1. Grading system for intravesical prostatic protrusion (IPP). (A) Grade I (＜5 mm), (B) Grade II (5-10 mm), and (C) Grade III 
(＞10 mm) IPP. IPP, intravesical prostatic protrusion.
ing symptoms by causing more serious bladder outlet ob-
struction (BOO) [2-4]. The most accurate method for diag-
nosing BOO is a pressure flow study (PFS). However, non-
invasive methods are being sought as substitutes, because 
of the invasiveness, cost, and morbidity associated with 
PFS. Measurement of IPP has the advantages that it is re-
producible, has parameters and correlations established 
by conventional PFS, and does not require urination dur-
ing the test [5].
It is reported that increased IPP due to an enlarged pros-
tate may aggravate storage symptoms as a consequence of 
elongation of the prostatic urethra and increased stim-
ulation of the bladder neck and trigone. Moreover, the in-
creased IPP can affect storage symptoms more than void-
ing symptoms owing to stimulation of the bladder [6-9]. 
Therefore, the aim of this work was to examine the effect 
of different IPP levels as estimated by TRUS on changes 
in the voiding and storage symptoms of BPH patients, the 
general progress of patients after daily administration of 
tamsulosin 0.2 mg, and the effectiveness of the medication.
MATERIALS AND METHODS
The study included 134 men over 40 years of age with lower 
urinary tract symptoms (LUTS) who visited our clinic be-
tween January 2007 and January 2009, retrospectively. 
All men underwent urinalysis, routine laboratory tests, 
measurement of prostate-specific antigen (PSA), uroflow-
metry (Urodyn-1000; Medtronic Inc., West Palm Beach, 
FL, USA), 6.5 MHz probe TRUS (SA-8000, Medison, Seoul, 
Korea), and measurement of post-voided residual (PVR) 
volume by ultrasonography. In patients with PSA≥4 
ng/ml, we performed TRUS-guided biopsies to rule out 
prostate cancer and enrolled the patients who were not di-
agnosed with prostate cancer. Degrees of initial Interna-
tional Prostate Symptom Scores and Quality of Life (IPSS/ 
QoL) score, prostate volume, maximal urine flow rate 
(Qmax), and PVR were not considered as exclusion criteria. 
The following subjects were excluded from the study: those 
who had histories of gross hematuria, urinary tract in-
fection, urinary tract stone disease, or pelvic surgery; those 
with a diagnosis of neurogenic bladder or urethral stric-
ture; and those using anticholinergic agents and 5-al-
pha-reductase inhibitors. Using TRUS, retrospectively, 
we identified the bladder neck and protrusion of the pros-
tate into the bladder according to the classification system 
of IPP as used by Nose et al. [5]. By measuring the vertical 
distance from the tip of the protrusion to the circumference 
of the bladder at the base of the prostate gland, we divided 
the patients into 3 groups according to the extent of IPP: 
those with an IPP of 5 mm or less (group A), those with an 
IPP of 5 to 10 mm (group B), and those with an IPP of greater 
than 10 mm (group C) (Fig. 1). Prostate volume, transi-
tional zone volume (TZV), prostatic urethral length (PUL), 
and prostatic adenoma urethral length (PAUL) were esti-
mated by TRUS. PUL and PAUL were measured as the ver-
tical distance from the base of the prostate gland to the apex 
of the prostate gland and to the apex of the prostate ad-
enoma, respectively, by retrospective review. IPSS/QoL 
scores were obtained for all patients, and IPSS scores were 
subdivided according to irritative subscore and obstructive 
subscore. The scores on the first visit were compared with 
those obtained after administration of tamsulosin 0.2 mg 
for 3 months. Uroflowmetry measurements were also com-
pared before and after tamsulosin administration. 
Each characteristic was compared among the groups by 
one-way analysis of variance test. The relation of each vari-
able with IPP was examined by correlation and multiple 
linear regression analysis. The IPSS/QoL, Qmax, and PVR 
before and after tamsulosin 0.2 mg administration were 
compared by using Student’s paired t-test. Statistical anal-
yses were performed with Open Office.org Calc ver. 3.2.1 
(Oracle Co., Redwood Shores, CA, USA) and MedCalc ver. 
11.2.1.0 (MedCalc Software, Mariakerke, Belgium). A p
＜0.05 was considered statistically significant.
RESULTS
The mean age of the patients was 65.01±7.38 years. Mean 
prostate volume and mean TZV were 47.11±21.45 ml and 
21.57±14.75 ml, respectively. Mean PSA was 4.26±4.34 
ng/ml. Mean IPSS total score, irritative subscore, ob-
structive subscore, and QoL were 18.72±7.17, 7.46±3.37, 
11.27±4.47, and 3.87±1.08, respectively.   
Mean Qmax was 10.86±4.99 ml/s and mean PVR was 
77.36±78.71 ml. Mean IPP was 4.31±5.96 mm, mean PUL Korean J Urol 2012;53:92-97
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TABLE 1. Characteristics of patients in Groups A, B, and C
Total
(n=134)
Group A
(n=90)
Group B
(n=24)
Group C
(n=20)
p-value
a
A vs. B vs. C A vs. B A vs. C B vs. C
PSA (ng/ml)
Age (yr)
Prostate volume (ml)
Transitional zone 
volume (ml)
PSA density (ng/ml
2)
IPP (mm)
PUL (cm)
PAUL (cm)
  4.26±4.34
65.01±7.38
  47.11±21.45
  21.57±14.75
  0.09±0.08
   4.31± 5.96
  4.56±0.08
  3.39±0.82
  3.46±3.83
64.03±7.71
  40.43±16.10
  17.12±10.55
  0.08±0.08
  0.90±1.39
  4.29±0.63
  3.11±0.59
  4.61±4.09
64.13±5.80
  50.11±22.31
  23.85±15.00
  0.09±0.08
  6.92±1.10
  4.71±0.68
  3.56±0.76
  7.48±5.34
66.70±5.30
  73.50±21.31
  38.86±17.72
  0.10±0.06
16.60±4.06
  5.63±0.70
  4.46±0.90
0.001
0.061
＜0.001
＜0.001
0.392
＜0.001
＜0.001
＜0.001
0.479
0.998
0.070
0.073
0.637
＜0.001
＜0.001
0.015
0.001
0.054
＜0.001
＜0.001
0.513
＜0.001
＜0.001
＜0.001
0.076
0.076
＜0.001
0.001
0.975
＜0.001
＜0.001
＜0.001
Values are presented as mean±SD.
PSA, prostate-specific antigen; IPP, intravesical prostatic protrusion; PUL, prostatic urethral length; PAUL, prostatic adenoma ure-
thral length.
a: analysis of variance.
TABLE 2. Correlations between intravesical prostatic protrusion 
(IPP) and prostate volume/International Prostate Symptom 
Score (IPSS)/uroflowmetry parameters before tamsulosin 0.2 
mg administration
Parameters
IPP (mm)
Correlation 
coefficient
p-value
a
Age (yr)
PSA (ng/ml)
TRUS
Total volume
TZV
PUL (cm)
PAUL (cm)
Uroflowmetry
Qmax (ml/s)
PVR (ml)
IPSS
Total score
Irritative subscore  
Obstructive subscore
QoL score
0.29
0.22
0.56
0.54
0.63
0.61
-0.28
0.37
0.12
0.12
0.11
0.12
 0.17
 0.01
＜0.001
＜0.001
＜0.001
＜0.001
   0.001
＜0.001
 0.16
 0.16
 0.22
 0.19
PSA, prostate-specific antigen; TRUS, transrectal ultrasonogra-
phy; TZV, transitional zone volume; PUL, prostatic urethral 
length; PAUL, prostatic adenoma urethral length; Qmax, max-
imal urine flow rate; PVR, post-voided residual; QoL, Quality of 
Life.
a: Correlation analysis. 
was 4.56±0.08 cm, and mean PAUL was 3.39±0.82 cm. 
Average IPP values of the groups were as follows: group A, 
0.90±1.39 mm; group B, 6.92±1.10 mm; group C, 16.60± 
4.06 mm. Among the three groups, all characteristics 
showed statistical significance (Table 1) not including age 
and PSA density. Correlation analysis indicated that pros-
tate volume (r=0.56, p＜0.001), PUL (r=0.63, p＜0.001), 
PAUL (r=0.61, p＜0.001), and PSA (r=0.22, p=0.01) varied 
with IPP. The same was true for Qmax (r=-0.28, p=0.001) 
and PVR (r=0.37, p＜0.001), whereas IPSS total scores and 
subscores and QoL were unrelated to IPP before tamsulo-
sin 0.2 mg administration (Table 2). 
Table 3 compares IPSS total scores, subscores, QoL, 
Qmax, and PVR in the groups before and after admin-
istration of 0.2 mg tamsulosin for 3 months. In the total pa-
tients, IPSS total score (p＜0.001), subscores (p＜0.001), 
QoL (p＜0.001), and Qmax (p＜0.001) were significantly 
improved after treatment. However, PVR did not show 
statistical significance. In group A, IPSS total score (p
＜0.001), subscores (p＜0.001), QoL (p＜0.001), Qmax (p
＜0.001), and PVR (p=0.03) were significantly reduced af-
ter treatment. In group B, the same was true for IPSS total 
score (p=0.01), irritative subscore (p＜0.001), and ob-
structive subscore (p=0.03), but not for QoL (p=0.15), Qmax 
(p=0.25), or PVR (p=0.39). Whereas in group C, only the 
IPSS total score (p=0.01) and IPSS irritative subscore (p
＜0.001) were significantly lower. By multiple linear re-
gression analysis to evaluate IPP as a predictive factor, on-
ly IPP was statistically significantly related to whether 
both IPSS and Qmax were improved (IPSS, p=0.044; 
Qmax, p＜0.001) (Table 4).
DISCUSSION
IPP refers to a morphological change in which the prostate 
protrudes into the bladder during the process of prostatic 
enlargement [10]. A median lobe of prostate tissue can in-
crease bladder outlet resistance by causing a ‘valve ball’ 
type of BOO with incomplete opening of the bladder neck 
and disruption of its funneling effect [11]. The IPSS ques-
tionnaire and measurements of PSA, prostate volume, 
urine flow, and PVR can be useful in deciding on the treat-
ment for LUTS/BPH; however, it is difficult to decide be-
tween medication and surgical treatment solely on the ba-
sis of these tests. In addition, the existence of BOO needs 
to be demonstrated. PFS is the reference standard for diag-
nosing BOO and differentiating this condition from de-Korean J Urol 2012;53:92-97
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TABLE 3. Comparison of IPSS total score and subscores, QoL, Qmax, and PVR in Groups A, B, and C after 3 months tamsulosin 0.2 
mg administration
Variable Total Group A Group B Group C p-value
a
IPSS total score
Baseline
Endpoint
p-value
b
IPSS irritative subscore
Baseline
Endpoint
p-value
b
IPSS obstructive subscore
Baseline
Endpoint
p-value
b
QoL
Baseline
Endpoint
p-value
b
Qmax (ml/s)
Baseline
Endpoint
p-value
b
PVR (ml)
Baseline
Endpoint
p-value
b
18.72±7.17
12.37±7.18
＜0.001
  7.46±3.37
  4.90±3.02
＜0.001
11.27±4.47
  7.43±4.52
＜0.001
  3.87±1.08
  3.19±1.13
＜0.001
10.86±4.99
12.75±4.53
＜0.001
  77.36±78.71
    58.03±101.06
  0.06
18.17±7.88
10.92±6.93
＜0.001
  7.21±3.63
  4.38±2.71
＜0.001
10.96±4.88
  6.54±4.54
＜0.001
  3.78±1.17
  2.99±1.12
＜0.001
11.72±5.48
13.88±4.48
＜0.001
  64.13±55.85
  30.76±27.23
  0.03
18.21±5.47
12.92±5.25
  0.01
  7.29±2.96
  4.42±1.64
＜0.001
10.92±3.12
  8.50±3.92
  0.03
  3.96±0.81
  3.42±0.97
  0.15
10.54±3.18
12.75±2.52
  0.25
  57.08±21.52
  69.88±39.26
  0.39
21.85±4.56
18.20±7.56
  0.01
  8.75±2.20
  7.80±3.96
＜0.001
13.10±3.55
10.10±3.87
  0.31
  4.20±0.89
  3.80±1.11
  0.28
  7.35±2.32
  7.70±3.03
  0.45
  161.20±139.45
  166.55±223.72
  0.58
0.107
＜0.001
0.175
＜0.001
0.139
0.002
0.263
0.007
0.001
＜0.001
＜0.001
＜0.001
Values are presented as mean±SD.
IPSS, International Prostate Symptom Score; QoL, Quality of Life; Qmax, maximal urine flow rate; PVR, post-voided residual.
a: ANOVA was performed for Groups A, B, and C, 
b: Student’s t-test was performed between baseline and endpoint values. 
TABLE 4. Multiple linear regression analysis of the various 
factors affecting treatment outcome
Variables
IPSS
a Qmax
a
Beta p-value Beta p-value
IPP (mm) 0.20 0.044 0.79 ＜0.001
PSA (ng/ml) -0.05 0.630 0.16 0.026
PSA density (ng/ml
2) 0.08 0.355 0.09 0.158
Baseline IPSS -0.05 0.412 0.01 0.991
Baseline Qmax (ml/s) -0.01 0.956 0.05 0.419
Prostate volume (ml) -0.02 0.937 -0.05 0.730
TZV (ml) 0.04 0.870 -0.06 0.696
IPSS, International Prostate Symptom Score; Qmax, maximal 
urine flow rate; IPP, intravesical prostatic protrusion; PSA, pros-
tate-specific antigen; TZV, transitional zone volume.
a: The difference between baseline and endpoint.
trusor underactivity [12]. However, the need for PFS in pa-
tients with BPH has been questioned. PFS cannot be ap-
plied to all patients because of its invasiveness, the dis-
comfort that can be caused, and the possibility of infection. 
Noninvasive methods, including IPSS/QoL, Qmax, PVR, 
prostate volume, and IPP have been studied as potential 
substitutes for PFS. The European Association of Urology 
guidelines on the assessment of BPH recommend that PFS 
should be used only in patients with a voided volume of less 
than 150 ml, patients with a maximum urine ﬂow greater 
than 15 ml/s prior to surgery, patients who are very young 
(＜50 years) or very old (＞80 years), and patients with post-
void residual urinary volumes greater than 300 ml, suspi-
cion of neurogenic bladder dysfunction, postradical pelvic 
surgery, or previous unsuccessful invasive treatment of 
BPH [13]. Recently, TRUS and IPP have been separately 
proposed as useful noninvasive parameters for predicting 
BOO in patients with LUTS/BPH [14].
Chia et al. [11] suggested that IPP may be a diagnostic 
tool for predicting BOO in patients with LUTS/BPH. They 
found that grade III IPP correctly identified 94% of ob-
structed patients. Nose et al. [5] showed that the IPP grad-
ing system and Doppler urodynamic study have high sensi-
tivities and specificities in the prediction of BOO. Lim et 
al. [2] who analyzed 95 patients with LUTS/BPH and asso-
ciated IPP, concluded that only IPP was independently as-
sociated with BOO. However, they reported that severe 
IPP of ＞10 mm correctly predicted 71% of patients with 
BOO, whereas IPP of ≤10 mm identified only 61% of pa-
tients without BOO. Keqin et al. [15] analyzed 206 patients 
with enlarged prostates. They concluded that IPP was pos-
itively correlated with prostate volume, detrusor over-
activity, bladder compliance, detrusor pressure at Qmax, 
BOO index, and PVR. Recently, Kim and Kim [16] inves-Korean J Urol 2012;53:92-97
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tigated the correlation between degree of IPP and IPSS/ 
QoL in 179 patients. They concluded that overactive blad-
der may be correlated with IPP. In another study, no sig-
nificant correlation was observed between IPP grading and 
initial IPSS score; however, the evolution of the IPSS score 
was helpful in assessing clinical progression [17]. In our 
study, baseline IPSS/QoL scores did not show significant 
correlation with IPP grades among all groups. However, in 
comparison with end-point IPSS, percentage improve-
ment in the IPSS score was higher in group A than in groups 
B and C (39.91% vs. 29.05% vs. 16.70%). In the present 
work, we found that the number of factors improved by tam-
sulosin 0.2 mg decreased in patients with higher IPP 
grades. According to previous studies, IPP is significantly 
correlated with increased prostate volume, transitional 
zone volume, PSA, decreased Qmax, and increased PVR. 
IPP has also been shown to be correlated with worsening 
of urination symptoms by BOO. In our patients, medication 
with tamsulosin yielded better responses in patients with 
lower IPP grades, and there was greater resistance to treat-
ment in patients with higher grades. Furthermore, ob-
jective measurements did not show any improvements in 
the patients with higher IPP grades. In relation to PUL and 
PAUL in LUTS/BPH patients, no studies have yet been 
reported. As IPP increases, PUL and PAUL might con-
comitantly increase and thus were evaluated in our study. 
In the correlation analysis, PUL and PAUL showed a pos-
itive correlation with degree of IPP (PUL, ＜0.001; PAUL, 
＜0.001).     
Despite these advantages, IPP does not replace estab-
lished parameters used in the clinical evaluation of BPH, 
such as IPSS/QoL, uroflowmetry, PVR, and prostate 
volume. IPP provides additional clinical information for 
predicting obstruction without the need for routine PFS. 
Also, IPP is not correlated with initial IPSS scores. 
However, it might help in devising treatment plans be-
cause of its advantages over other measurements, not its 
limitations. 
There have been many studies of the correlation between 
IPP and BOO. However, these generally focused on the re-
lation between the morphology of the prostate and BOO. 
In our study, we focused on clinical progression and found 
that in the patients with higher IPP grades, clinical symp-
toms, especially obstructive symptoms, were resistant to 
the administration of tamsulosin 0.2 mg for 3 months.
We acknowledge the potential limitations of this study: 
it was a retrospective study, the study population was 
small, and the enrolled patients did not undergo PFS, 
which is the standard method for distinguishing between 
BOO and detrusor contractility. In addition, measurement 
of IPP, PUL, and PAUL was performed retrospectively and 
may have induced several biases in our study. However, de-
spite the possible bias, the results of this study suggest that 
IPP may help in evaluating LUTS/BPH and in deciding on 
a therapeutic plan with medical or surgical treatment.
CONCLUSIONS
IPP shows significant correlations with increased prostate 
volume, PUL, PAUL, PSA, decreased Qmax, and increased 
PVR. Patients with different levels of IPP differed with re-
spect to the benefits achieved by a tamsulosin dose of 0.2 
mg for 3 months. IPP was correlated with obstructive 
symptoms, and improvements of obstructive symptoms, 
Qmax, and PVR were more resistant to medical treatment 
as the level of IPP increased. 
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